Oncternal Therapeutics Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Oncternal Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Oncternal Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Oncternal Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 37.1 M |
Oncternal |
Oncternal Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Oncternal Therapeutics on December 24, 2024 and sell it today you would earn a total of 100.00 from holding Oncternal Therapeutics or generate -100.0% return on investment over 90 days. Oncternal Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Oncternal, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncternal Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncternal Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncternal Therapeutics, and traders can use it to determine the average amount a Oncternal Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ONCT |
Based on monthly moving average Oncternal Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncternal Therapeutics by adding Oncternal Therapeutics to a well-diversified portfolio.
Oncternal Therapeutics Fundamentals Growth
Oncternal Stock prices reflect investors' perceptions of the future prospects and financial health of Oncternal Therapeutics, and Oncternal Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncternal Stock performance.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (17.57) % | ||||
| Current Valuation | (12.83 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.17 X | ||||
| Price To Sales | 0.72 X | ||||
| Revenue | 785 K | ||||
| EBITDA | 2.23 M | ||||
| Cash And Equivalents | 78.9 M | ||||
| Cash Per Share | 1.48 X | ||||
| Total Debt | 318 K | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 3.09 X | ||||
| Cash Flow From Operations | (32.16 M) | ||||
| Earnings Per Share | (11.69) X | ||||
| Total Asset | 36.73 M | ||||
| Retained Earnings | (197.78 M) | ||||
| Current Asset | 27.27 M | ||||
| Current Liabilities | 6.3 M | ||||
Things to note about Oncternal Therapeutics performance evaluation
Checking the ongoing alerts about Oncternal Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncternal Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncternal Therapeutics is not yet fully synchronised with the market data | |
| Oncternal Therapeutics has some characteristics of a very speculative penny stock | |
| Oncternal Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 785 K. Net Loss for the year was (39.48 M) with loss before overhead, payroll, taxes, and interest of (31.49 M). | |
| Oncternal Therapeutics currently holds about 78.9 M in cash with (32.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.48. |
- Analyzing Oncternal Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncternal Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Oncternal Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncternal Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncternal Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncternal Therapeutics' stock. These opinions can provide insight into Oncternal Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |